Molecular pathophysiology of theantiphospholipid syndrome: The role of oxidative post-translational modification of beta 2 glycoprotein I

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 1 S, 2011, Pages 275-282

  Passam, F H ^a   Giannakopoulos, B ^a   Mirarabshahi, P ^a   Krilis, S A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Antiphospholipid syndrome; Beta 2 glycoprotein I; Post translational modification; S nitrosylation; S oxidation; Tyrosine nitration

Indexed keywords

BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CYSTEINE; EPITOPE; GLUTATHIONE; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; NITROGEN OXIDE; PHOSPHOLIPID ANTIBODY; REACTIVE OXYGEN METABOLITE; S NITROSOGLUTATHIONE; S NITROSOTHIOL;

ANGIOGENESIS; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; APOPTOSIS; ARTERY THROMBOSIS; CELL ACTIVATION; CELL PROTECTION; CORONARY ARTERY; ELECTRON MICROSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SYNTHESIS; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR PATHOLOGY; MOLECULAR WEIGHT; MORBIDITY; MORTALITY; NITROSYLATION; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN PROCESSING; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; THROMBOCYTE ACTIVATION; THROMBOSIS; VEIN THROMBOSIS; BLOOD; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BETA 2-GLYCOPROTEIN I; HUMANS; OXIDATION-REDUCTION; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 79960646137     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04301.x     Document Type: Review

References (48)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Roldan V, Lecumberri R, Munoz-Torrero JF, Vicente V, Rocha E, Brenner B, Monreal M. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res 2009; 124: 174-7.
3. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet 2010; 376: 1498-509.
4. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990; 87: 4120-4.
5. Meroni PL, Peyvandi F, Foco L, Bernardinelli L, Fetiveau R, Mannucci PM, Tincani A. Anti-beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women. J Thromb Haemost 2007; 5: 2421-8.
6. Urbanus RT, Siegerink B, Roest M, Rosendaal FR, de Groot PG, Algra A. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998-1005.
7. Jankowski M, Vreys I, Wittevrongel C, Boon D, Vermylen J, Hoylaerts MF, Arnout J. Thrombogenicity of beta 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-62.
8. Arad A, Proulle V, Furie RA, Furie BC, Furie B. {beta}2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011; 117: 3453-9.
9. Lozier J, Takahashi N, Putnam FW. Complete amino acid sequence of human plasma beta 2-glycoprotein I. Proc Natl Acad Sci U S A 1984; 81: 3640-4.
10. Kamboh MI, Ferrell RE, Sepehrnia B. Genetic studies of human apolipoproteins. IV. Structural heterogeneity of apolipoprotein H (beta 2-glycoprotein I). Am J Hum Genet 1988; 42: 452-7.
11. Miyakis S, Giannakopoulos B, Krilis SA. Beta 2 glycoprotein I--function in health and disease. Thromb Res 2004; 114: 335-46.
12. Hunt JE, Simpson RJ, Krilis SA. Identification of a region of beta 2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci U S A 1993; 90: 2141-5.
13. Giannakopoulos B, Mirarabshahi P, Krilis SA. New insights into the biology and pathobiology of beta2-glycoprotein I. Curr Rheumatol Rep 2011; 13: 90-5.
14. Yasuda S, Tsutsumi A, Chiba H, Yanai H, Miyoshi Y, Takeuchi R, Horita T, Atsumi T, Ichikawa K, Matsuura E, Koike T. beta(2)-glycoprotein I deficiency: prevalence, genetic background and effects on plasma lipoprotein metabolism and hemostasis. Atherosclerosis 2000; 152: 337-46.
15. Sheng Y, Reddel SW, Herzog H, Wang YX, Brighton T, France MP, Robertson SA, Krilis SA. Impaired thrombin generation in beta 2-glycoprotein I null mice. J Biol Chem 2001; 276: 13817-21.
16. Matsuura E, Lopez LR. Autoimmune-mediated atherothrombosis. Lupus 2008; 17: 878-87.
17. Berndt C, Lillig CH, Holmgren A. Thiol-based mechanisms of the thioredoxin and glutaredoxin systems: implications for diseases in the cardiovascular system. Am J Physiol Heart Circ Physiol 2007; 292: H1227-36.
18. Martinez-Ruiz A, Lamas S. Signalling by NO-induced protein S-nitrosylation and S-glutathionylation: convergences and divergences. Cardiovasc Res 2007; 75: 220-8.
19. Bouma B, de Groot PG, van den Elsen JM, Ravelli RB, Schouten A, Simmelink MJ, Derksen RH, Kroon J, Gros P. Adhesion mechanism of human beta(2)-glycoprotein I to phospholipids based on its crystal structure. EMBO J 1999; 18: 5166-74.
20. Schwarzenbacher R, Zeth K, Diederichs K, Gries A, Kostner GM, Laggner P, Prassl R. Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. EMBO J 1999; 18: 6228-39.
21. Ioannou Y, Zhang JY, Passam FH, Rahgozar S, Qi JC, Giannakopoulos B, Qi M, Yu P, Yu DM, Hogg PJ, Krilis SA. Naturally occurring free thiols within beta 2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells, and regulation of oxidative stress-induced cell injury. Blood 2010; 116: 1961-70.
22. Ioannou Y, Zhang JY, Qi M, Lu G, Qi JC, Demin Y, Lau H, Sturgess A, Vlachoyiannopoulos P, Moutsopoulos H, Rahman A, Pericleous C, Atsumi T, Koike T, Heritier S, Giannakopoulos B, Krilis S. Assay of thrombogenic pathogenicity for the antiphospholipid syndrome: detection of oxidative modification of the major autoantigen ß2-glycoprotein I. Arthritis Rheum 2011. [in press].
23. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. Beta 2 glycoprotein I is a substrate of thiol oxidoreductases. Blood 2010; 116: 1995-7.
24. Agar C, van Os GM, Morgelin M, Sprenger RR, Marquart JA, Urbanus RT, Derksen RH, Meijers JC, de Groot PG. Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010; 116: 1336-43.
25. Reddel SW, Wang YX, Sheng YH, Krilis SA. Epitope studies with anti-beta 2-glycoprotein I antibodies from autoantibody and immunized sources. J Autoimmun 2000; 15: 91-6.
26. Hulstein JJ, Lenting PJ, de Laat B, Derksen RH, Fijnheer R, de Groot PG. beta2-Glycoprotein I inhibits von Willebrand factor dependent platelet adhesion and aggregation. Blood 2007; 110: 1483-91.
27. Passam FH, Rahgozar S, Qi M, Raftery MJ, Wong JW, Tanaka K, Ioannou Y, Zhang JY, Gemmell R, Qi JC, Giannakopoulos B, Hughes WE, Hogg PJ, Krilis SA. Redox control of beta2-glycoprotein I-von Willebrand factor interaction by thioredoxin-1. J Thromb Haemost 2010; 8: 1754-62.
28. Lin KY, Wang HH, Lai ST, Pan JP, Chiang AN. beta(2)-glycoprotein I protects J774A.1 macrophages and human coronary artery smooth muscle cells against apoptosis. J Cell Biochem 2005; 94: 485-96.
29. Lin KY, Pan JP, Yang DL, Huang KT, Chang MS, Ding PY, Chiang AN. Evidence for inhibition of low density lipoprotein oxidation and cholesterol accumulation by apolipoprotein H (beta2-glycoprotein I). Life Sci 2001; 69: 707-19.
30. Sheikh Z, Ahmad R, Sheikh N, Ali R. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies. Autoimmunity 2007; 40: 512-20.
31. Buttari B, Profumo E, Mattei V, Siracusano A, Ortona E, Margutti P, Salvati B, Sorice M, Rigano R. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005; 106: 3880-7.
32. Hattori N, Kuwana M, Kaburaki J, Mimori T, Ikeda Y, Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000; 43: 65-75.
33. Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, Kawakami Y. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005; 105: 1552-7.
34. Arai T, Yoshida K, Kaburaki J, Inoko H, Ikeda Y, Kawakami Y, Kuwana M. Autoreactive CD4(+) T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood 2001; 98: 1889-96.
35. Sheng Y, Sali A, Herzog H, Lahnstein J, Krilis SA. Site-directed mutagenesis of recombinant human beta 2-glycoprotein I identifies a cluster of lysine residues that are critical for phospholipid binding and anti-cardiolipin antibody activity. J Immunol 1996; 157: 3744-51.
36. Iverson GM, Victoria EJ, Marquis DM. Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI. Proc Natl Acad Sci U S A 1998; 95: 15542-6.
37. Iverson GM, Reddel S, Victoria EJ, Cockerill KA, Wang YX, Marti-Renom MA, Sali A, Marquis DM, Krilis SA, Linnik MD. Use of single point mutations in domain I of beta 2-glycoprotein I to determine fine antigenic specificity of antiphospholipid autoantibodies. J Immunol 2002; 169: 7097-103.
38. Chiu WC, Chen CJ, Lee TS, Chen ZJ, Ke PH, Chiang AN. Oxidative stress enhances AP-1 and NF-kappaB-mediated regulation of beta(2)-glycoprotein I gene expression in hepatoma cells. J Cell Biochem 2010; 111: 988-98.
39. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, Bohgaki T, Amengual O, Amasaki Y, Koike T. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004; 16: 1633-41.
40. Zhou H, Wolberg AS, Roubey RA. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004; 104: 2353-8.
41. Sorice M, Longo A, Capozzi A, Garofalo T, Misasi R, Alessandri C, Conti F, Buttari B, Rigano R, Ortona E, Valesini G. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007; 56: 2687-97.
42. Robbins DL, Leung S, Miller-Blair DJ, Ziboh V. Effect of anticardiolipin/beta2-glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome. J Rheumatol 1998; 25: 51-6.
43. Shi T, Giannakopoulos B, Yan X, Yu P, Berndt MC, Andrews RK, Rivera J, Iverson GM, Cockerill KA, Linnik MD, Krilis SA. Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V. Arthritis Rheum 2006; 54: 2558-67.
44. Pennings MT, Derksen RH, van Lummel M, Adelmeijer J, VanHoorelbeke K, Urbanus RT, Lisman T, de Groot PG. Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost 2007; 5: 369-77.
45. Essex DW. Redox control of platelet function. Antioxid Redox Signal 2009; 11: 1191-225.
46. Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, Khamashta MA, Tremoli E, Camera M. Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 2870-8.
47. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, Bossi F, Ziller F, Sblattero D, Meroni P, Tedesco F. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106: 2340-6.
48. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, Zeher MM, Tincani A, Kontopoulou-Griva I, Galeazzi M, Bellisai F, Meroni PL, Derksen RH, de Groot PG, Gromnica-Ihle E, Baleva M, Mosca M, Bombardieri S, Houssiau F, Gris JC, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68: 1428-32.